1. Alternative Routes of Administration of Clozapine

   • Siobhan Gee
   • David Taylor

   Current Opinion 03 February 2022 Pages: 105 - 111

2. Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?

   • Meir Bialer
   • Emilio Perucca

   Leading Article 30 January 2022 Pages: 113 - 122

   

3. Potential Role of Curcumin for the Treatment of Major Depressive Disorder

   • Adrian L. Lopresti

   Leading Article Open access 07 February 2022 Pages: 123 - 141

   

4. Pharmacological Management of Apathy in Dementia

   • Laiba Azhar
   • Raphael W. Kusumo
   • Nathan Herrmann

   Review Article 10 January 2022 Pages: 143 - 165

5. Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies

   • Lauren Chiec
   • Priya Kumthekar

   Review Article 25 January 2022 Pages: 167 - 179

6. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model

   • Drew MacCannell
   • Zdenek Berger
   • Francesco Muntoni

   Original Research Article Open access 26 January 2022 Pages: 181 - 190

   

7. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score

   • Luigi Francesco Iannone
   • Davide Fattori
   • Francesco De Cesaris

   Original Research Article Open access 11 February 2022 Pages: 191 - 202

   

8. Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“

   • Marco Pappagallo
   • Charles E. Inturrisi
   • Paolo L. Manfredi

   Letter to the Editor Open access 11 January 2022 Pages: 203 - 204

9. Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”

   • Ioline D. Henter
   • Lawrence T. Park
   • Carlos A. Zarate Jr.

   Letter to the Editor 11 January 2022 Pages: 205 - 206